Trinomab completed its STAR Market IPO, raising 999 million yuan. Its core product, the world's first recombinant anti-tetanus toxin monoclonal antibody drug, Staidatamab injection, was approved for marketing in February 2025, priced at 798 yuan per vial. In the same year, it achieved drug sales revenue of 51.2249 million yuan, but actual sales volume of 159,000 vials reached only 57% of expectations. From 2023 to 2025, the company accumulated a net loss attributable to the parent of 1.562 billion yuan. In 2025, selling expenses surged to 190 million yuan, 3.7 times the current period's revenue. In the first quarter of this year, due to the implementation of medical insurance pricing, revenue soared year-on-year to 24.9289 million yuan, and the net loss narrowed to 96.4965 million yuan. The company expects revenue of 71 million to 74 million yuan in the first half of 2026, with a loss of 201 million to 204 million yuan.
Changchun BCHT Biotechnology Co. ASales volume of core drug Staidatamab reached only 57% of expectations, indicating weak end-customer demand